|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although PTC-CCV may demonstrate features that overlap with those of the classic variant of PTC, hypercellular smears with papillary structures covered by cells with pseudostratified nuclei that show a paucity of nuclear pseudoinclusions and grooves should alert the cytopathologist to the possibility of this diagnosis.Cancer Cytopathol 2017;125:389-97.© 2017 American Cancer Society.
|
28374549 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although ret/PTC rearrangements have been identified in both spontaneous and radiation-induced papillary thyroid cancer, they seem more frequent among radiation-associated tumors.
|
15126554 |
2004 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although the cause of the high frequency of RET/PTC oncogenes in Chinese papillary thyroid carcinomas is unknown, our study suggests that RET rearrangement is an important genetic lesion underlying the development of thyroid papillary carcinoma in Taiwan.
|
9589668 |
1998 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As a model system, we selected human thyroid papillary cancer, in which the most common abnormalities, RET/papillary thyroid cancer rearrangements (fusion of RET kinase domain to the activating domains of other genes), were found in 40--45% of cases.
|
11889175 |
2002 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As PAX8/PPARG and RET/PTC rearrangements have been detected in follicular thyroid carcinomas (FTCs) and papillary thyroid carcinomas (PTCs), their detection in FNA smears could improve the FNA diagnosis.
|
23025542 |
2012 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ATC with PTC components is typically characterised by a BRAF mutation with a late mutation event, whereas PDTC with PTC components is more closely correlated with RET fusion.
|
31230400 |
2019 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BACKGROUND RET rearrangements have been reported in 30% of papillary thyroid carcinomas and 1-2% of non-small cell lung cancer (NSCLC).
|
30429449 |
2018 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Because RET/PTC gene rearrangements are specific to papillary thyroid carcinoma, the authors examined the presence of RET/PTC-1, -2, and -3 in eight hyalinizing trabecular tumors using reverse transcription-polymerase chain reaction with Southern hybridization and immunohistochemistry.
|
11117782 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because RET/PTC rearrangements are unique to thyroid carcinomas, our findings support the clinical evaluation of sorafenib for patients with PTC and the identification of patients most likely to respond to sorafenib treatment.
|
18676765 |
2008 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because of similarities in involvement of the two tyrosine kinases RET (rearranged during transfection) and NTRK1 in the pathogenesis of PTC, the obvious parallels between RET and NTRK1 and between PTC and medullary thyroid carcinoma (MTC), NTRK1 seemed to be an excellent candidate gene to play a role in the genesis of MTC.
|
10443680 |
1999 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Both phosphatases were studied in three PCCL3 rat thyroid cell lines that express doxycycline inducible PTC oncogenes (RET/PTC3, H-RASV12 or BRAFV600E).
|
28910386 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BRAF and RET/PTC are the most frequent driving genetic lesions identified in PTC.
|
24810336 |
2014 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation is mutually exclusive with RET/PTC rearrangement, and also displays a reciprocal age association with this common genetic alteration in thyroid cancer.
|
15947100 |
2005 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation detected on FNAB specimens, more than RET/PTC rearrangements, is highly specific for PTC and its routine research might well be an adjunctive and integrative diagnostic tool for the preoperative diagnostic iter.
|
17727338 |
2007 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BRAF-associated PTC differ profoundly from RET/PTC or RAS-associated cancers.
|
21798995 |
2011 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BRAFV600E and RET/PTC-positive PTCs were histologically similar.
|
26258321 |
2015 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma.
|
8634704 |
1995 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
By the higher sensitive Southern-blot on RT-PCR method, RET rearrangements were present in 36% of papillary thyroid carcinomas (RET/PTC-1, 12%; RET/PTC-3, 20%; both, 4%) and of 13.3% of benign nodules.
|
21173509 |
2011 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cases were evaluated for rearranged in transformation/papillary thyroid carcinoma RET/PTC rearrangement by fluorescent in situ hybridization (FISH).
|
20924280 |
2010 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CCI = Charlson Comorbidity Index; CCR = California Cancer Registry; CI = confidence interval; DTC = differentiated thyroid cancer; FTC = follicular thyroid carcinoma; HCC = Hürthle cell carcinoma; IQR = interquartile range; mPTC = papillary thyroid micro-carcinoma; OR = odds ratio; OSPHD = Office of Statewide Health Planning and Development; PTC = papillary thyroid carcinoma.
|
28816539 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Cells of 8505-C and KTC-1 harbor the BRAF(V600E) mutation, and TPC-1 has the RET/PTC rearrangement.
|
20470206 |
2010 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Certain mutations, such as mutations of BRAF in papillary thyroid carcinoma and mutations in RET codons 883, 918, and 928, are associated with an aggressive course in medullary thyroid carcinoma, and affected patients need close surveillance.
|
27618325 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Classic genetic rearrangements in papillary carcinoma of the thyroid involve the RET- or TRK proto-oncogenes.
|
11678839 |
2001 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Classic-type PTC was associated with a larger prevalence of alterations, predominantly BRAF and RET/PTC, whereas the follicular variant was chiefly associated with RAS.
|
22150560 |
2012 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CLN = central lymph node; PTC = papillary thyroid carcinoma; PTMC = papillary thyroid microcarcinoma.
|
30289307 |
2018 |